<DOC>
	<DOCNO>NCT01833169</DOCNO>
	<brief_summary>The purpose signal seek study determine whether treatment BKM120 demonstrate sufficient efficacy select pathway-activated solid tumor and/or hematologic malignancy warrant study .</brief_summary>
	<brief_title>BKM120 Patients With PI3K-activated Tumors</brief_title>
	<detailed_description />
	<criteria>Patient confirm diagnosis solid tumor hematological malignancy exception endometrial cancer , glioblastoma , nonsmall cell lung cancer , prostate cancer breast cancer . Patient 's tumor evaluate preidentified activation PI3K pathway , CLIA certify laboratory Patient must receive least one prior treatment recurrent metastatic /or locally advance disease standard therapy option anticipate result durable remission . Patient must progressive measurable disease per RECIST 1.1. appropriate hematological guideline Patient Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Patient receive previous treatment BKM120 Patient symptomatic CNS metastases Patient mood disorder outline Section 5 Patient receive chemotherapy anticancer therapy ≤ 4 week ( 6 week nitrosourea , antibody mitomycinC ) prior start study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>malignancy</keyword>
	<keyword>hematologi malignancy</keyword>
	<keyword>PI3K pathway activation</keyword>
	<keyword>BKM120</keyword>
	<keyword>signature</keyword>
	<keyword>AML , acute myelogenous leukemia</keyword>
	<keyword>cervical , ovarian</keyword>
	<keyword>hepatobiliary</keyword>
	<keyword>buparlisib</keyword>
</DOC>